Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
5.71
-0.47 (-7.61%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.34 - 5.90
52 week 5.34 - 28.97
Open 5.74
Vol / Avg. 738,176.00/468,152.00
Mkt cap 159.55M
P/E     -
Div/yield     -
EPS -1.57
Shares 28.94M
Beta 1.06
Inst. own 122%
Feb 24, 2016
Q4 2015 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 11, 2016
Aegerion Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Jan 14, 2016
Aegerion Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 14, 2016
Aegerion Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 11, 2016
Preliminary Q4 2015 Aegerion Pharmaceuticals Inc Net Product Sales
Nov 18, 2015
Aegerion Pharmaceuticals Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -14.51% -24.87%
Operating margin -3.55% -16.86%
EBITD margin - -16.09%
Return on average assets -8.68% -14.07%
Return on average equity -26.57% -28.82%
Employees 295 -
CDP Score - -

Address

1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company's products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Officers and directors

Sandford D. Smith Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Mary T. Szela Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gregory D. Perry Chief Financial and Administrative Officer
Age: 54
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
William Andrews Senior Vice President - Business Development
Age: 50
Bio & Compensation  - Reuters
Martha Carter Senior Vice President, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
David Aubuchon Chief Accounting Officer
Bio & Compensation  - Reuters
Donald K. Stern Esq. Director
Bio & Compensation  - Reuters
Sol J. Barer Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D.,Ph.D Independent Director
Age: 79
Bio & Compensation  - Reuters